

11. A system according to claim 9 wherein the lentivirus is HIV.

B3
12. A system according to claim 1 wherein the third nucleotide sequence is resistant to cleavage directed by the gene product as a result of one or more conservative alterations in the nucleotide sequence which remove cleavage sites recognised by the at least one gene product and/or binding sites for the at least one gene product.

13. A system according to claim 1 wherein the third nucleotide sequence is adapted to be resistant to cleavage by the at least one gene product.

14. A system according to claim 1 wherein the third nucleotide sequence is codon optimised for expression in producer cells.

16. A system according to claim 1 comprising a plurality of first nucleotide sequences and third nucleotide sequences as defined therein.

17. A viral particle comprising a viral vector genome as defined in claim 3 and one or more third nucleotide sequences as defined in claim 3.

18. A viral particle produced using a viral vector production system according to claim 3.

19. A method for producing a viral particle which method comprises introducing into a host cell (i) a viral genome as defined in claim 3 (ii) one or more third nucleotide sequences as defined in claim 3 and (iii) nucleotide sequences encoding the other essential viral packaging components not encoded by the one or more third nucleotide sequences.

21. A pharmaceutical composition comprising a viral particle according to claim 17, together with a pharmaceutically acceptable carrier or diluent.

Please add the following new claim:

B5
--24. (New) A method of treating a viral infection, comprising administering to a subject infected with a virus an effective amount of a viral system according to claim 1.--